Table 1.
Characteristics of cardiac ADRs associated with immune checkpoint inhibitor therapy in Vigibase (last accessed 11/23/2019)+*.
Table 2.
Number of cardiac events associated with immune checkpoint inhibitor monotherapy or combination therapy by indication (total n = 2 631, reporting n (%)).
Table 3.
Number of reports, expected count, empirical Bayes estimator (EBE), and reporting odds ratio (ROR) for cardiac adverse drug reactions in patients receiving immune checkpoint inhibitor monotherapy or combination therapy.
Fig 1.
Cumulative incidence of time to carditis onset from initiation of immune checkpoint inhibitor monotherapy (turquoise) or combination therapy (pink).